Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the ...
Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
18hon MSN
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...
Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...
Today’s drop in Moderna’s price moves the company’s stock to its lowest levels since April 2020. Shares now trade 93% lower ...
In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...
Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...
14h
“In the end," Vrabel said. "It was clear to me, and to my family, and my soul, that this was the place that I wanted to be.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback